- Family Elder
- Posts: 269
- Joined: Sat Nov 28, 2009 3:00 pm
- Location: Victoria, BC Canada
<don't shoot me, I'm just the messenger >
-begin forwarded message -
<I removed the text as per cheer's suggestion. It was third or fouth-hand information, so I am sure it will surface elsewhere. In addition, it was sent to the department, not one individual, so it's "out there."
In any case, it's gone (for now).>
http://neurology.stanford.edu/profiles/ ... s&fid=8456
Jeffrey Dunn, MD
Stanford physicians and scientists may interact with the pharmaceutical, biotech, or medical device industries to help develop new medical drugs, devices or diagnostics or to provide medical education about health care related topics of mutual interest. Their interactions are reviewed annually as part of Stanford University School of Medicine policy. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company to physicians and faculty scientists from companies or other commercial entities with which they interact as part of their professional activities. These payments, including cash, equity, equity options and royalties can arise from a variety of activities including consulting, services on boards, educational activities and licensing agreements. In providing this information, Stanford tries to be as informative as possible concerning its faculty's interactions with industry. The following relationships have been reported with the companies listed below during the calendar year 2008. To learn more about Stanford's policies on collaborations with industry go to http://med.stanford.edu/coi
Consulting: Dr. Dunn receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
* Accorda Pharmaceuticals, Bayer Healthcare, Biogen Idec, EMD Serono, Gilead Sciences, Teva Neuroscience
Royalty Payments: Dr. Dunn consults for and receives royalty payments of $5,000 or more for inventions or discoveries related to the following companies:
Equity: Dr. Dunn owns stock or stock options (if the equity is valued at $5,000 or more, and the company is publicly traded and/or equity if the company is privately held) in the following companies for activities as a founder, inventor, or consultant:
Service on Board of Directors: Dr. Dunn serves in a fiduciary capacity, such as an officer or director, for the following companies or other entities:
alright I'll delete mine tooo - too bad i thought it was funny!!!
PALO ALTO, Calif.--(BUSINESS WIRE)--April 27, 2004
Professor Lawrence Steinman, MD, of Stanford Medical Center and Founder of Bayhill Therapeutics, has been chosen by a committee of his peers to receive the 2004 John Dystel Prize for Multiple Sclerosis (MS) Research. Dr. Steinman is being honored for his major contributions to scientific understanding of MS-like disease models, and for translating these findings to the development of novel therapeutic strategies for people with MS.
"MS starts in a few trees and then starts burning the whole forest," said Lawrence Steinman, MD, a ...
SAN MATEO, Calif. -- Bayhill Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA[TM] platform to develop novel and targeted autoimmune disease treatments, today announced that Lawrence Steinman M.D., Professor of Neurology, Pediatrics and Genetics at Stanford University and Founder, Director and Scientific Advisory Board Chairman of Bayhill Therapeutics, has been awarded an endowed chair at Stanford as the George A. Zimmerman Professor. Dr. Steinman is the inaugural holder of the chair, funded to support multiple sclerosis (MS) ...
Nuon Therapeutics' founding scientists, Marc Feldmann, MD, PhD and Larry Steinman, MD, have conducted wide-ranging preclinical testing of tranilast.
Professor Steinman is professor, Departments of Neurology and Neurological Sciences, Stanford University, and a specialist in multiple sclerosis (MS).His research identified the biological pathways that led to the development the MS therapeutic, TysabriÂ®.Professor Steinman's work with tranilast showing improvement in an animal model of MS was published in the journal Science.
The company's scientific founders are Prof. Larry Steinman at Stanford University, Palo Alto, Prof. Marc Feldmann, Imperial College, London, and Dr. Michael Selley, formerly from the Australian National University.
Collaborative MS Research Center Award
Lawrence Steinman, MD
Stanford University, Palo Alto, Calif.
http://www.nationalmssociety.org/resear ... index.aspx
So it will interesting to see if he comes on board with CCSVI, especially if it receives funding, or if he goes looking for more pharma monies.
What else is Stanford going to say, "throw the doors open everyone come on in?". Of course not. If I had the choice between angioplasty and nothing, you know which one I would pick in a heartbeat. (meaning of course that I think angioplasty will replace stenting for the time being)They cannot stop this and if not here then somewhere else. It's not over by a long shot, but I am saddened so many hopes got up for a procedure then were dashed, albeit temporarily from my POV.
And also to toss in there, just how far Dr. Dake went out on a limb for us, all needs aside to improve the procedure and such.
- Family Elder
- Posts: 5359
- Joined: Mon Sep 10, 2007 2:00 pm
- Location: southern California
- Been thanked: 1 time
I'm so sorry for everyone that cannot have their VASCULAR problems addressed by this caring and committed surgeon because NEUROLOGISTS have stopped this treatment, but I will continue to update on the CCSVI page and work with the doctors involved.
I do think this e-mail should probably be removed, since it was not intended for public viewing, and must violate some privacy law -
I'm sure NHE will advise.
dx dual jugular vein stenosis (CCSVI) 4/09
Plus, who the hell wants their institution to get screwed over if the adverse events increase in number and they are faced with lawsuits? Unless we have more trials, his statement is not out of line at all where he says: "this is a procedure that cannot be defended, supported or recommended on risk-benefit considerations at this time." Even the non-pharma affiliated doctors at NIH are saying this.
Clinical trials are good...let's be glad that they are at least considering that.
But the second there is a problem, and that's not to make it a light problem, it IS serious and needs to be addressed, they all of the sudden *realize* that surgeries are being performed on MS patients? Come off it already, they knew all along and chose to allow it, that implies tacit approval, without having to look at an email, and now the SHTF they disavow it completely?
Like Mom used to say, "Come off it already".
- Family Elder
- Posts: 338
- Joined: Wed Jan 05, 2005 3:00 pm
- Location: Massachusetts, USA
Besides the whole tone issue as noted by Rokkit, this is actually the part that got to me. There are many, many doctors and patients who can defend, support and recommend this procedure. Perhaps the risk-benefit considerations seem off from the MS Clinic's perspective, and I can appreciate that, but it is not logical or fair to apply that statement globally.Unless we have more trials, his statement is not out of line at all where he says: "this is a procedure that cannot be defended, supported or recommended on risk-benefit considerations at this time."
As many of us who have had or wanted this procedure have noted, everyone is going to feel differently about the risks. There is a risk in doing nothing. There is a risk in taking other MS meds. No one knows when the seeds of disability start to form. No one knows what implications of opening the veins are for MS.
But there are many, many who recommend opening up occluded jugular veins because the benefits far outweigh the risks.
1 stent placed in left jugular vein 7/15/09
on and off Copaxone
allergric to interferons and Tysabri